Narrow-Moat Shire Remains Undervalued Despite Early Lialda Generics and Hemophilia Threats
We’re slightly lowering our Shire fair value estimate to $218/GBX 5,500 following a solid second quarter, largely due to earlier-than-anticipated Lialda competition (in the second half of 2017) and an increase in our cost of capital to account for recent debt repayment. We continue to think that the shares look undervalued, however, as Lialda stands out as one of the few products that we think is vulnerable to dramatic sales declines with generic entrants. Hemophilia competition to Feiba (from R...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.